-
Recursion Pharmaceuticals reported Q3 2026 revenue of US$18.55 million and a net loss of US$119.04 million, while highlighting an extended cash runway into 2029, new financing and ongoing pharma collaborations.
-
Fresh Phase 2 data for REC-4881 in familial adenomatous polyposis showed meaningful and durable reductions in polyp burden with a generally manageable safety profile, reinforcing the clinical relevance of Recursion Pharmaceuticals' AI-driven discovery platform.
-
The focus now turns to how Recursion Pharmaceuticals' improved loss profile and REC-4881 data could influence the longer term investment narrative.
Seize this moment around Recursion Pharmaceuticals' AI-driven drug work to review a curated group of healthcare-focused data and algorithm specialists through 38 healthcare AI stocks .
Recursion Pharmaceuticals Investment Narrative Recap
To own Recursion Pharmaceuticals, you need to believe its AI driven discovery engine can keep turning large datasets and automation into drug candidates that matter clinically and commercially. The latest quarter showed revenue of US$18.55 million and a loss of US$119.04 million, so the story is still about platform productivity rather than near term earnings.
In the short run, the key swing factor is whether REC 4881 and REC 1245 keep producing data that support bigger trials and potential partnership economics. The main risk remains the scale of ongoing losses and spend. Any slowdown in pipeline progress or milestone receipts could make that cash burn harder to tolerate, even with a runway guided into 2029.
The fresh Phase 2 TUPELO data for REC 4881 in familial adenomatous polyposis appears to be the headline operational update tied to this earnings print. Management reported broad reductions in total polyp burden across upper and lower GI tracts, including larger, higher risk polyps, with a generally manageable safety profile across 26 evaluable patients.
For you as a shareholder, REC 4881 now sits near the center of the medium term thesis because the company plans a registrational trial targeted for the second half of 2027, subject to FDA discussions. That timeline makes study design decisions, ClinTech execution and ongoing safety readouts important potential catalysts, while any clinical setback here would directly affect the perceived value of Recursion Pharmaceuticals' broader AI platform.
Recursion Pharmaceuticals' analyst narrative points to forecast revenue of US$116.3 million and earnings of US$20.7 million by 2029. This assumes 28.5% yearly revenue growth and an earnings swing of roughly US$539.6 million from earnings today of a US$518.9 million loss.
Uncover why Recursion Pharmaceuticals' fair value indicates a potential upside of 89% to its current price, a gap that could narrow quickly.
Exploring Other Perspectives
One alternate angle to watch is REC-1245. The most optimistic analysts were already sketching out a far steeper path, with revenue forecasts around US$382.1 million and earnings near US$65.7 million by 2029, before this quarter and the REC-4881 update. Whether you lean cautious or upbeat, these numbers show that opinions can differ sharply. It is worth comparing several viewpoints and deciding where you sit.
Explore 6 other Recursion Pharmaceuticals fair value estimates , including one that suggests as much as 158% upside from the current price!
Decide For Yourself
Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.
-
A great starting point for your Recursion Pharmaceuticals research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.
-
See our latest analysis for Recursion Pharmaceuticals. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Recursion Pharmaceuticals' overall financial health at a glance.
Looking For More Investment Ideas Beyond Recursion Pharmaceuticals?
If Recursion Pharmaceuticals has sharpened your interest in AI driven drug development, it can help to widen the lens and compare it with other opportunities that match your risk profile and income goals. The Simply Wall St Screener lets you filter companies quickly so you can focus on a shortlist that actually fits how you want to invest.
-
If you want potential bargains with quality fundamentals, start with a focused set of 33 high quality undervalued stocks that already clear basic balance sheet and cash flow checks.
-
For investors who care most about capital preservation and steadier profiles, narrow your search to 33 resilient stocks with low risk scores that score well on key risk indicators.
-
If income is a priority, filter for 5 dividend fortresses that combine higher yields with the kind of stability many dividend investors look for.
This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include RXRX .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
